Form 4 for EW Edwards Lifesciences
Accepted 2021-08-02 00:00:00 ET · period of report 2021-08-02 · accession 0001225208-21-011037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-02 | 2021-08-02 | EW | Szyman Catherine M. | CVP, Critical Care | S - Sale+OE | $113.53 | -15.0K | 27.8K | -35% | -$1.70M |
| D | 2021-08-02 | 2021-08-02 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $21.76 | +15.0K | 42.8K | +54% | +$326.4K |
| D | 2021-08-02 | 2021-08-02 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -15.0K | 132.9K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-02 | S | D | 15,000 | $113.53 | 27,758.91 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $113.4450 to $113.7500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2021-08-02 | M | A | 15,000 | $21.76 | 42,758.91 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2021-08-02 | M | D | 15,000 | $0.00 | 132,882 | D | $21.76 · 2016-05-14 to 2022-05-13 | 15,000 Common Stock |